Share this Article
Fatima A, Khawaja KI, Burney S, Minhas K, Mumtaz U, Masud F
Correspondence: Dr Faisal Masud, dr.faisalmasud@gmail.com
ABSTRACT
Introduction With advancement in the understanding of the pathogenesis underlying diabetes mellitus (DM), the boundary between type 1 and type 2 DM (T1DM and T2DM) does not seem to be as clear cut as previously thought. This study was designed to test the possibility of overlap between the spectra of immune-mediated DM and insulin resistance.
Methods To test for the possibility of overlap, we looked for autoantibodies typical of T1DM in patients with classical T2DM, and insulin resistance in patients with T1DM. Autoantibodies against islet cell antigen, glutamic acid decarboxylase-65 and insulinoma-associated antigen-2 were tested in 82 patients with T2DM and 27 patients with T1DM. The patients had been diagnosed on clinical criteria using standard laboratory techniques. Clinical parameters of diagnostic importance were noted, and homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using fasting insulin and fasting blood glucose ratio.
Results Autoantibodies against one or more beta cell antigens were detected in 12.19% of patients clinically diagnosed to have T2DM, and insulin resistance (HOMA-IR > 2.5) was diagnosed in 37.03% of patients with T1DM. It was not possible to identify any combination of clinical or biochemical markers that could predict autoantibody positivity in T2DM patients. T1DM patients with insulin resistance had a significantly higher body mass index than their insulin-sensitive counterparts (p = 0.02).
Conclusion Autoantibodies against beta cell antigens are detectable in insulin-resistant T2DM patients, and insulin resistance may be present in relatively overweight T1DM patients. No differentiating clinical features that might predict autoantibody positivity in T2DM patients were found.
Keywords: autoantibodies, insulin resistance, type 1 diabetes mellitus, type 2 diabetes mellitus
Singapore Med J 2013; 54(7): 396-400; http://dx.doi.org/10.11622/smedj.2013141
REFERENCES
| 1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 Suppl 1:64-71. http://dx.doi.org/10.2337/dc12-s064 | ||||
| 2. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9. http://dx.doi.org/10.1007/BF00280883 | ||||
| 3. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57:158-61. http://dx.doi.org/10.1373/clinchem.2010.148270 | ||||
| 4. Tsui H, Paltser G, Chan Y, Dorfman R, Dosch HM. 'Sensing' the link between type 1 and type 2 diabetes. Diabetes Metab Res Rev 2011; 27:913-8. http://dx.doi.org/10.1002/dmrr.1279 | ||||
| 5. Nadeau KJ, Regensteiner JG, Bauer TA et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 2010; 95:513-21. http://dx.doi.org/10.1210/jc.2009-1756 | ||||
| 6. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167:40-6. http://dx.doi.org/10.1111/j.1365-2249.2011.04501.x | ||||
| 7. Negishi M, Shimomura K, Proks P, et al. An obese patient with slowly progressive type 1 diabetes diagnosed by ketoacidosis. Intern Med 2010; 49:393-5. http://dx.doi.org/10.2169/internalmedicine.49.2843 | ||||
| 8. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1:111-5. http://dx.doi.org/10.4239/wjd.v1.i4.111 | ||||
| 9. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 2006. | ||||
| 10. Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-1 and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35:768-73. http://dx.doi.org/10.2337/dc11-1833 | ||||
| 11. Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27:1798-811. http://dx.doi.org/10.2337/diacare.27.7.1798 | ||||
| 12. LaFontaine T. Physical Activity: The Epidemic of Obesity and Overweight Among Youth: Trends, Consequences, and Interventions. American Journal of Lifestyle Medicine 2008; 2:30-36. http://dx.doi.org/10.1177/1559827607309688 | ||||
| 13. Suzuki T, Takahashi K, Miyamoto S, et al. "Type 1 on type 2" diabetes mellitus: autoimmune type 1 diabetes superimposed on established type 2 diabetes. Intern Med 2007; 46:1957-62. http://dx.doi.org/10.2169/internalmedicine.46.0282 | ||||
| 14. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1487-95. http://dx.doi.org/10.2337/diacare.27.6.1487 | ||||
| 15. Szadkowska A, Pietrzak I, Bodalska-Lipi?ska J, et al. [Insulin resistance in young type 1 diabetic patients]. Diabetologia Do?wiadczalna i Kliniczna 2006; 6:293-8. Polish. | ||||
| 16. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007; 30:2314-20. http://dx.doi.org/10.2337/dc06-2389 | ||||
| 17. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care 2011; 34 Suppl 2:166-70. http://dx.doi.org/10.2337/dc11-s213 | ||||
| 18. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type 1 diabetes. J Autoimmun 1996; 9:379-83. http://dx.doi.org/10.1006/jaut.1996.0051 | ||||
| 19. Winter WE, Harris N, Schatz D. Immunologic markers in the diagnosis and prediction of autoimmune, type 1A diabetes. Clinical Diabetes 2002; 20:183-91. http://dx.doi.org/10.2337/diaclin.20.4.183 | ||||
| 20. Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005; 19:119-33. http://dx.doi.org/10.1016/j.beem.2004.11.010 | ||||
| 21. Zimmet PZ, Tuomi T, Mackay IR. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11:299-303. http://dx.doi.org/10.1111/j.1464-5491.1994.tb00275.x | ||||
| 22. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 4:703-8. http://dx.doi.org/10.1007/s00125-005-1691-9 | ||||
| 23. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57:168-75. http://dx.doi.org/10.1373/clinchem.2010.148205 | ||||
| 24. Juneja R, Hirsch IB, Naik RG, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50:1008-13. http://dx.doi.org/10.1053/meta.2001.25654 | ||||
| 25. Turner R, Stratton I, Horton V, et al. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes (UKPDS 25). Lancet 1997; 350:1288-93. http://dx.doi.org/10.1016/S0140-6736(97)03062-6 | ||||
| 26. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51:1754-62. http://dx.doi.org/10.2337/diabetes.51.6.1754 | ||||
| 27. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86:3032-8. http://dx.doi.org/10.1210/jc.86.7.3032 | ||||
| 28. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45:622-6. http://dx.doi.org/10.2337/diabetes.45.5.622 | ||||
| 29. Anastasi E, Dotta F, Tiberti C, et al. Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. Autoimmunity 1995; 29:249-56. http://dx.doi.org/10.3109/08916939908994743 | ||||